TOMM40 poly-T Variants Influence Sensitivity to Lorezapam-induced Impairment in Healthy Elderly
Nunzio Pomara, MD, professor, Department of Psychiatry, NYU School of Medicine, director of Geriatric Psychiatry, Nathan S. Kline Institute
EMBARGOED FOR RELEASE UNTIL SUNDAY, JULY 17, 2011 AT 12:30pm CEST (6:30am ET/USA)
Healthy and cognitively-intact elderly carriers of APOE e4, an established risk factor for late-onset Alzheimer's disease(LOAD), display more pronounced memory deficits following acute administration of lorazepam, a drug used to alleviate anxiety, than non-e4 carriers. However, among non-e4 carriers, there is considerable individual variability. Researchers found a biomarker that could help predictor which individuals were more likely to have suffer memory losses associated with the drug.
Impact of Hormone Replacement Therapy (HRT) Usage on Seven Year Outcome of Older Persons with Subjective Cognitive Impairment
Barry Reisberg, MD, professor in the Department of Psychiatry, NYU School of Medicine
EMBARGOED FOR RELEASE UNTIL SUNDAY, JULY 17, 2011 AT 3pm CEST (9amET/USA)
In this study of 91 women with subjective cognitive impairment, 22 received hormone replacement therapy either as estrogen or estrogen-progesterone combined. Of the HRT group, 45.5% progressed to either mild cognitive impairment or dementia over a 7-year period. The researchers conclude that HRT did not influence the progression of SCI. Systematic longitudinal investigation of possible effects of other medications on progression of SCI to MCI/dementia is required to identify substances that may regulate or prevent this process.
|Contact: Lorinda Klein|
NYU Langone Medical Center / New York University School of Medicine